Les références en gras ont été publiées par les membres de MATHEC
2024
Harnessing the potential of CAR-T cell in lupus treatment: From theory to practice
Tamim Alsuliman, Marjanovic Z, Rimar D, Tarte K, Avcin T, Hagen M, Schett G, Farge D
Autoimmun Rev . 2024 Nov 10;23(12):103687. doi: 10.1016/j.autrev.2024.103687.
BCMA-Targeted T-Cell–Engager Therapy for Autoimmune Disease
Hagen M, Bucci L, Böltz S, Nöthling D-M, Rothe T, Anoshkin K, Raimondo M G, Tur C, Wirsching A, Jochen Wacker, Alexander F, Düsing C, Distler J H.W, Heine H, Kuwert T, Bozec A, Ramming A, Schett G, Grieshaber-Bouyer R
N Engl J Med 2024;391:867-869 published September 4, 2024 doi: 10.1056/NEJMc2408786
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
Wang X,n Wu X, Tan B, Zhu L, Zhang Y, Lin L, Xiao Y, Sun A, Wan X, Liu S, Liu Y, Ta N, Zhang H, Song J, Li T, Zhou L, Yin J, Ye L, Lu H, Hong J, Cheng H, Wang P, Li W, Chen J, Zhang J, Luo J, Huang M, Guo L, Pan X, Jin Y, Ye W, Dai L, Zhu J, Sun L, Zheng B, Li D, He Y, Liu M, Wu H, Du B, Xu H
Cell 187, 1–15 July 15, 2024 DOI:https://doi.org/10.1016/j.cell.2024.06.027
Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production
Dingfelder J, Aigner M, Taubmann J, Minopoulou I, Park S, Kaplan C D, Cheng J K, Van Blarcom T, Schett G, Mackensen A, Lutzny-Geier G
Transplantation and Cellular Therapy Volume 30, Issue 6, June 2024, Pages 582.e1-582.e10, doi.org/10.1016/j.jtct.2024.03.023
Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis
Haghikia A, Hegelmaier T, Wolleschak D, Böttcher M, Pappa V, Motte J, Borie D, Gold R, Feist E, Schett G, Mougiakakos D
Ann Rheum Dis. 2024 Jun 27:ard-2024-226017. doi: 10.1136/ard-2024-226017. Online ahead of print.
Successful use of anti- CD19 CAR T cells in severe treatment-refractory stiff-person syndrome
Faissner S, Motte J, Sgodzai M, Geis C, Haghiki A, Mougiakakos D, Borie D, Schroers R, Gold R
PNAS June 17, 2024 121 (26) e2403227121 https://doi.org/10.1073/pnas.2403227121
Autologous CD19- targeting CAR T cells in refractory juvenile dermatomyositis
Nicolai R, Merli P, Alvarez P M, Bracaglia C, Del Bufalo F, Marasco E, Caiello I, Prencipe G, Algeri M, Cefalo M G, Becilli M, Quintarelli C, Sinibaldi M, Hanssens L, De Benedetti F, Locatelli F
Arthritis Rheumatol. 2024 Jun 24. doi: 10.1002/art.42933. Online ahead of print.
Dawn of CAR-T cell therapy in autoimmune diseases
Yuxin L, Minghao D, Yunhui C, Luoqi Z, Yunfan Y, Xiaowei P, Sheng Y, Luyang Z, Lian C, Lifang Z, Jun X, Wei W, Chuan Q, Daishi T,
Chinese Medical Journal 137(10):p 1140-1150, May 20, 2024. DOI: 10.1097/CM9.0000000000003111
Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells
Motte J, Sgodzai M, Schneider-Gold C, Steckel N, Mika T, Hegelmaier T, Borie D, Haghikia A, Mougiakakos D, Schroers R, Gold R
Neuron Available online 1 May 2024 https://doi.org/10.1016/j.neuron.2024.04.014
Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies
Chasov V, Zmievskaya E, Ganeeva I, Gilyazova E, Davletshin D, Khaliulin M, Kabwe E, Davidyuk YN, Valiullina A, Rizvanov A, Bulatov E
Antibodies (Basel). 2024 Feb 1;13(1):10. doi: 10.3390/antib13010010.
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, Aigner M, Rothe T, Minopoulou I, Tur C, Knitza J, Kharboutli S, Kretschmann S, Vasova I, Spoerl S, Reimann H, Munoz L, Gerlach R G, Schäfer S, Grieshaber-Bouyer R, Korganow A-S, Farge-Bancel D, Mougiakakos D, Bozec A, Winkler T, Krönke G, Mackensen A, and Schett G
N Engl J Med. 2024 Feb 22;390(8):687-700. doi: 10.1056/NEJMoa2308917.
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee
Greco R , Alexander T, Del Papa N, Müller F, Saccardi R, Sanchez-Guijo F, Schett G, Sharrack B, Snowden J A, Tarte K, Onida F, Sánchez-Ortega I, Burman J, Castilla Llorente C, Cervera R, Ciceri F, Doria A, Henes J, Lindsay J, Mackensen A, Muraro P A, Ricart E, Rovira M, Zuckerman T, Yakoub-Agha I and Farge D
EClinicalMedicine. 2024 Feb 10:69:102476. doi: 10.1016/j.eclinm.2024.102476. eCollection 2024 Mar.
B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis
Tian D-S, Qin C, Dong M-H, Heming M , Zhou L-Q, Wang W, Cai S-B, You Y-F, Shang K, Xiao J, Wang D, Li C-R, Zhang M, Bu B-T, zu Hörste G M, Wang W
EMBO Mol Med (2024) 16: 966 – 987 https://doi.org/10.1038/s44321-024-00043-z
Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy
Qin C, Dong M-H, Zhou L-Q, Wang W, Cai S-B, You Y-F, Shang K, Xiao J, Wang D, Li C-R, Zhang M, Bu B-T, Tian D-S, Wang W,
PNAS 2024 Vol. 121 No. January 30, 2024 121 (6) e2315990121 doi.org/10.1073/pnas.2315990121
2023
Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis
Merkt W, Freitag M, Claus M, Kolb P, Falcone V, Röhrich M, Rodon L, Deicher F, Andreeva I, Tretter T, Tykocinski L-O, Blank N, Watzl C, Schmitt A, Sauer T, Müller-Tidow C, Polke M, Heußel C P, Dreger P, Lorenz H-M, Schmitt M
Ann Rheum Dis. 2023 Dec 22:ard-2023-225174. doi: 10.1136/ard-2023-225174.
Concurrent remission of lymphoma and Sjögren’s disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report
Sheng L, Zhang Y, Song Q, Jiang X, Cao W, Li L, Yi H, Weng X, Chen S, Wang Z, Wu W, Wang L, Zhao W and Yan Z
Front. Immunol., 19 December 2023 Sec. B Cell Biology Volume 14 – 2023 | https://doi.org/10.3389/fimmu.2023.1298815
Anti-CD19 CAR T cells for refractory myasthenia gravis
Haghikia A, Hegelmaier T, Wolleschak D, Böttcher M, Desel C, Borie D, Motte J, Schett G, Schroers R, Gold R, Mougiakakos D
Lancet Neurol. 2023 Dec;22(12):1104-1105. doi: 10.1016/S1474-4422(23)00375-7.
CAR T cells for treating autoimmune diseases
Blache U, Tretbar S, Koehl U, Mougiakakos D, Fricke S
RMD Open. 2023 Nov 23;9(4):e002907. doi: 10.1136/rmdopen-2022-002907.
CAR T-cell therapy in autoimmune diseases
Schett G, Mackensen A, Mougiakakos D
Lancet. 2023 Sep 22;S0140-6736(23)01126-1. doi: 10.1016/S0140-6736(23)01126-1.
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study
Granit V, Benatar M, Kurtoglu M, Miljković MD, Chahin N, Sahagian G, Feinberg MH, Slansky A, Vu T, Jewell CM, Singer MS, Kalayoglu MV, Howard Jr JF, Mozaffar T; MG-001 Study Team
Lancet Neurol. 2023 Jul;22(7):578-590. doi: 10.1016/S1474-4422(23)00194-1.
CD19-Targeting CAR T Cells forMyositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome
Pecher AC, Hensen L, Klein R, Schairer R, Lutz K, Atar D, Seitz C, Stanger A, Schneider J, Braun C, Schmidt M, Horger M, Bornemann A, Faul C, Bethge W, Henes J, Lengerke C.
JAMA. 2023;329(24):2154-2162. doi:10.1001/jama.2023.8753
CAR-Based Therapy for Autoimmune Diseases: A Novel Powerful Option
Muzes G and Sipos F
Cells 2023, 12, 1534.https://doi.org/10.3390/ cells12111534
Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol
Lalu M M, Kekre N, Montroy J, Ghiasi M, Hay K, McComb S, Weeratna R, Atkins H, Hutton B, Yahya A, Masurekar A, Sobh M, Fergusson D A
Syst Rev. 2023; 12: 9.Published online 2023 Jan 19. doi: 10.1186/s13643-022-02158-1
Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results
Qin C,Tian DS, Zhou LQ, Shang Ke, Huang L, Dong MH, You YF, Xiao J, Xiong Y, Wang W, Pang H, Guo JJ, Cai SB, Wang D, Li CR, Zhang,M, Bu BT, Wang W.
Signal Transduct Target Ther. 2023 Jan 4;8(1):5. doi: 10.1038/s41392-022-01278-3.
2022
CAR T therapy extends its reach to autoimmune diseases
Baker D J and June C H
Cell Volume 185, Issue 24, 23 November 2022, Pages 4471-4473. doi.org/10.1016/j.cell.2022.10.026
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, Simon D, Kleyer A, Munoz L, Kretschmann S, Kharboutli S, Gary S, Reimann H, Rösler W, Uderhardt S, Bang H, Herrmann M, Ekici A B, Buettner C, Habenicht K.M, Winkler TH, Krönke G, Schett G.
Nat Med. 2022 Oct;28(10):2124-2132. doi: 10.1038/s41591-022-02017-5.
Successful Generation of CD19 Chimeric Antigen Receptor T Cells from Patients with Advanced Systemic Lupus Erythematosus
Kretschmann S, Völkl S, Reimann H, Krönke G, Schett G, Achenbach S , Lutzny-Geier G, Müller F, Mougiakakos D, Dingfelder J, Flamann C, Hanssens L, Gary R, Mackensen A, Aigner M
Transplant Cell Ther. 2022 Oct 12;S2666-6367(22)01699-2. doi: 10.1016/j.jtct.2022.10.004.
2021
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, Böltz S, Manger B, Mackensen A, Schett G.
N Engl J Med. 2021 Aug 5;385(6):567-569. doi: 10.1056/NEJMc2107725.
Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus
Jin X, Xu Q,Pu C, Zhu K , Lu C, Jiang Y, Xiao L, Han Y, Lu L.
Cell Mol Immunol. 2021 Aug; 18(8): 1896–1903. doi: 10.1038/s41423-020-0472-1
2018
Chimeric Antigen Receptor Therapy
June C H and Sadelain M
N Engl J Med. 2018 Jul 5; 379(1): 64–73. doi: 10.1056/NEJMra1706169
2015
T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection
McKinney E F, Lee J C, Jayne D R W, Lyons P A, Smith K G C
Nature. 2015 Jul 30;523(7562):612-6. doi: 10.1038/nature14468. Epub 2015 Jun 29.